Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| BC BCDABioCardia | $1.01+4.4% | $15.3M | 4 assetsPhase 2 | No dated catalyst | |
| BC BCELAtreca Inc. | $0.09+0.0% | — | 1 assetsStage unavailable | No dated catalyst | |
| BC BCLIBrainstorm Cell Therapeutics | $0.98-7.5% | $10.8M |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
2 assetsStage unavailable |
| No dated catalyst |
| BC BCRXBioCryst Pharmaceuticals Inc. | $9.55-1.1% | $2.44B | 10 assetsApproved | BCX17725Phase 1 · Data readout |
| BC BCTXBriacell Therapeutics | $4.07+3.6% | $35.4M | 3 assetsStage unavailable | No dated catalyst |
| BC BCYCBicycle Therapeutics plc | $4.37+3.1% | $305.9M | 8 assetsPhase 2/3 | Zelenectide pevedotin (zele, formerly BT8009)Phase 2/3 · Data readout |
| BD BDTXBlack Diamond Therapy Inc. | $2.21+2.8% | $126.6M | 6 assetsStage unavailable | No dated catalyst |
| BE BEAMBeam Therapeutics Inc | $29.76+4.8% | $3.07B | 6 assetsPhase 1/2 | BEAM-302Phase 1/2 · Data readout |
| BF BFRIBiofrontera | $1.48+0.0% | $22.0M | 7 assetsPDUFA | Ameluz®-PDT combo w/ BF-RhodoLED®PDUFA · Approval decision |
| BG BGMSBio Green Med Solution | $0.87-1.2% | $5.7M | 2 assetsStage unavailable | No dated catalyst |
| BH BHVNBiohaven Pharmaceutical Holding Company | $13.85+2.6% | $2.09B | 19 assetsPhase 2/3 | BHV-1530Phase 1 · Data readout |
| BI BIIBBiogen | $216.78+1.1% | $32.03B | 27 assetsApproved | ZorevunersenPhase 3 · Data readout |
| BI BINVBioInvent International AB | $45.72+0.7% | — | 9 assetsPhase 2a | BI-1206 + KEYTRUDAPhase 2a · Data readout |
| BI BIOABioAge Labs | $9.48-2.2% | $435.1M | 2 assetsPhase 2 | BGE-102Phase 2 · Data readout |
| BI BIORBiora Therapeutics | $0.22+0.0% | $994,990 | 1 assetsStage unavailable | No dated catalyst |
| BI BIVIBioVie | $1.95+4.8% | $16.5M | 4 assetsPhase 2b | Bezisterim (NE3107)Phase 2 · Data readout |
| BL BLRXBioLineRx | $2.81+1.8% | $12.3M | 6 assetsPhase 2b | Motixafortide (BL-8040) w/ cemiplimabPhase 2b · Data readout |
| BL BLTEBelite Bio | $161.06-0.5% | $6.49B | 3 assetsPDUFA | Tinlarebant (LBS-008)PDUFA · Approval decision |
| BL BLUBellus Health | $14.74+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| BM BMEABiomea Fusion | $1.37+0.7% | $99.1M | 10 assetsPhase 2 | BMF-650 (GLP-1 RA)Phase 1 · Data readout |
| BM BMRNBiomarin Pharmaceutical Inc. | $66.70-1.4% | $12.91B | 12 assetsPhase 3 | No dated catalyst |
| BM BMYBristol-Myers Squibb | $67.01+2.4% | $136.88B | 62 assetsApproved | Camzyos/Mavacamten (MYK-461) (Myosin Inhibitor)PDUFA · Approval decision |
| BN BNTCBenitec Biopharma | $13.48+3.6% | $463.1M | 1 assetsStage unavailable | No dated catalyst |
| BN BNTXBioNTech SE | $116.57+5.1% | $29.28B | 30 assetsPhase 3 | BNT316 (ONC-392)Phase 3 · Data readout |
| BO BOLDBoundless Bio Inc | $3.00+3.4% | $68.2M | 2 assetsPhase 1/2 | BBI-940Phase 1/2 · Data readout |
| BO BOLTBolt Biotherapeutics | $3.67+14.5% | $7.1M | 3 assetsPhase 1 | BDC-4182Phase 1 · Data readout |
| BP BPMCBlueprint Medicines Corporation | $129.46+0.0% | $8.37B | 8 assetsStage unavailable | No dated catalyst |
| BP BPTHBio-Path Holdings Inc | $0.03-25.0% | $1.5M | 4 assetsStage unavailable | No dated catalyst |
| BR BRNSBarinthus Biotherapeutics plc [Formerly Vaccitech] | $0.62+1.5% | $25.4M | 13 assetsPhase 1 | VTP-1000Phase 1 · Data readout |
| BS BSGMBioSig Technologies | $6.10+37.1% | $215.2M | 2 assetsStage unavailable | No dated catalyst |
| BT BTAIBioXcel Therapeutics Inc | $0.80+0.7% | $25.2M | 9 assetsPDUFA | BXCL501PDUFA · Approval decision |
| BY BYSIBeyondSpring Pharmaceuticals | $0.72+0.0% | $29.6M | 5 assetsStage unavailable | No dated catalyst |
| CA CABACabaletta Bio | $3.13-1.9% | $530.7M | 7 assetsPhase 3 | Rese-cel (formerly CABA-201)Phase 1/2 · Data readout |
| CA CADLCandel Therapeutics | $13.13+6.3% | $1.00B | 6 assetsPhase 1b | CAN-3110Phase 1b · Data readout |
| CA CALACalithera Biosciences | $0.00+0.0% | $487 | 6 assetsStage unavailable | No dated catalyst |
| CA CALCCalciMedica | $0.57-1.8% | $17.6M | 7 assetsPhase 1b | Auxora/Zegocractin (Zegocractin) (CRAC Channel Inhibitor)Phase 1b · Data readout |
| CA CALTCalliditas Therapeutics | $40.00+0.0% | $1.10B | 6 assetsStage unavailable | No dated catalyst |
| CA CAMPCAMP4 Therapeutics | $4.48+0.4% | $281.1M | 2 assetsPhase 1b | No dated catalyst |
| CA CAPRCapricor Therapeutics | $6.29-8.0% | $365.7M | 3 assetsPDUFA | No dated catalyst |
| CA CARACara Therapeutics | — | — | 5 assetsStage unavailable | No dated catalyst |